IP15-20: Efficacy and safety of vibegron in men =75 years of age with symptoms of overactive bladder on pharmacotherapy for benign prostatic hyperplasia: a subgroup analysis of the COURAGE trial

IP15-20: Efficacy and safety of vibegron in men =75 years of age with symptoms of overactive bladder on pharmacotherapy for benign prostatic hyperplasia: a subgroup analysis of the COURAGE trial

Friday, May 15, 2026 1:00 PM to 3:00 PM · 1 hr. 59 min. (America/New_York)

146B

Abstract

Sessions

IP15: Benign Prostatic Hyperplasia: Epidemiology, Evaluation & Medical Non-surgical Therapy

Friday, May 15, 2026 1:00 PM to 3:00 PM

Log in

See all the content and easy-to-use features by logging in or registering!